Try our Advanced Search for more refined results

Expert Analysis

Inside The FTC's Take On Generic Access To Branded Drugs

Law360, New York (April 5, 2013, 11:39 AM EDT) -- The Federal Trade Commission has spent the better part of a decade pressing an expansive view of antitrust law in the context of patent settlement agreements between branded and generic pharmaceutical companies, culminating in last week's oral argument in FTC v. Actavis at the Supreme Court, where it met with a skeptical audience. Now, the FTC has entered previously uncharted ground by filing an amicus brief in a case addressing another issue of importance to the pharmaceutical industry: generic access to branded products for purposes of making Hatch-Waxman patent challenges....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!